Literature and medicine regulatory authorities reports present the secondary pharmacologic actions of mecasermin and mecasermin rinfabate, including the anabolic and insulin-like effects (i.e., hypoglycemia) [64,65,66]; these pharmacologic effects could place the drugs in the A–Alimentary tract and metabolism level 1 ATC, as predicted by our methodology (see Figure 9). Here, INS is linked to Hypoglycemia.